Ftse Mib
33.089,72
-0,23%
DAX
19.261,75
-0,22%
S&P 500
5.998,74
-0,38%
NASDAQ
19.060,48
-0,60%
Bitcoin
96.310,03
0,35%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Can Fite BioPharma Ltd (CANF) Can Fite BioPharma Ltd (CANF) Notizie

Can Fite BioPharma Ltd

CANF
2,16
0,11 (5,37%)
27 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/11/202422:48EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
11/11/202413:00GLOBECan-Fite Achieves Milestone with First Patient Dosing in..
04/11/202413:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/11/202413:08GLOBECan-Fite anti-Obesity Drug Namodenoson Received Patent..
18/10/202415:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202415:06GLOBESignificant Positive Results from Osteoarthritis Clinical ..
09/10/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/10/202413:00GLOBEFDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson..
07/10/202413:00GLOBEJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
24/9/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/9/202413:00GLOBEProjected Income of $325M to Can-Fite Over the Next 10 Years..
16/9/202413:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/9/202413:00GLOBECan-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with..
09/9/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
06/9/202422:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30/8/202422:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202422:18EDGAR2Form F-3 - Registration statement by foreign private issuers
30/8/202422:16EDGAR2Form POS AM - Post-Effective amendments for registration..
30/8/202422:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/8/202414:46EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202414:15GLOBECan-Fite Reports First Half 2024 Financial Results &..
12/8/202412:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202412:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202401:01GLOBECan-Fite Announces Exercise of Warrants for Approximately..
29/7/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/7/202413:00GLOBECan-Fite Provides Namodenoson Patent Update
17/7/202413:00GLOBEJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
11/7/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202413:00GLOBECan-Fite Applies for FDA Orphan Drug Designation for..
01/7/202413:00GLOBEImprovement in Patient with Decompensated Liver Cirrhosis..
28/6/202413:00BWPositive Results from Osteoarthritis Clinical Study in Dogs..
24/6/202413:00BWCan-Fite: Breakthrough Findings Demonstrate Namodenoson..
10/6/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/6/202413:00BWCan-Fite Received IRB Approval for the Treatment of..
07/6/202422:15EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
05/6/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202413:00BWCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase..
29/5/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/5/202413:00BWIndependent Scientists Published a Review Article..
27/5/202413:00BWCan-Fite to Participate in Partnering Meetings at Bio..
23/5/202413:00BWJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
22/5/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/5/202413:00BWCan-Fite: 75 Oncologists and Coordinators from Europe US and..
09/5/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202413:00BWCan-Fite: FDA Grants IND Clearance for Namodenoson to Treat..
06/5/202413:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202413:00BWCan-Fite Received Notice of Allowance from the European..
25/4/202413:00BWLong-term Complete Response to Can-Fite's Namodenoson in..
15/4/202413:00BWCan-Fite: Scientific Article Published by KOL Presents..
Apertura: 2,10 Min: 2,07 Max: 2,2499
Chiusura: 2,05

La tua Cronologia

AMEX
CANF
Can Fite BioPharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network